146 related articles for article (PubMed ID: 35049211)
1. Expression and clinical significance of BDH1 in liver cancer.
Liu Z; Li Y; Liu Y; Yang D; Jiao Y; Liu Y
Medicine (Baltimore); 2021 Dec; 100(48):e28013. PubMed ID: 35049211
[TBL] [Abstract][Full Text] [Related]
2. HN1 as a diagnostic and prognostic biomarker for liver cancer.
Liu Z; Yang D; Li Y; Jiao Y; Lv G
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32700728
[TBL] [Abstract][Full Text] [Related]
3. Deficiency of 3-hydroxybutyrate dehydrogenase (BDH1) in mice causes low ketone body levels and fatty liver during fasting.
Otsuka H; Kimura T; Ago Y; Nakama M; Aoyama Y; Abdelkreem E; Matsumoto H; Ohnishi H; Sasai H; Osawa M; Yamaguchi S; Mitchell GA; Fukao T
J Inherit Metab Dis; 2020 Sep; 43(5):960-968. PubMed ID: 32279332
[TBL] [Abstract][Full Text] [Related]
4. Cardiac-Specific Bdh1 Overexpression Ameliorates Oxidative Stress and Cardiac Remodeling in Pressure Overload-Induced Heart Failure.
Uchihashi M; Hoshino A; Okawa Y; Ariyoshi M; Kaimoto S; Tateishi S; Ono K; Yamanaka R; Hato D; Fushimura Y; Honda S; Fukai K; Higuchi Y; Ogata T; Iwai-Kanai E; Matoba S
Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29242353
[TBL] [Abstract][Full Text] [Related]
5. Diminished ketone interconversion, hepatic TCA cycle flux, and glucose production in D-β-hydroxybutyrate dehydrogenase hepatocyte-deficient mice.
Stagg DB; Gillingham JR; Nelson AB; Lengfeld JE; d'Avignon DA; Puchalska P; Crawford PA
Mol Metab; 2021 Nov; 53():101269. PubMed ID: 34116232
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study.
Wang Y; Huang Q; Deng T; Li BH; Ren XQ
Med Sci Monit; 2019 May; 25():3894-3901. PubMed ID: 31128068
[TBL] [Abstract][Full Text] [Related]
7. GPSM2 Serves as an Independent Prognostic Biomarker for Liver Cancer Survival.
Yang D; Ji F; Li Y; Jiao Y; Fang X
Technol Cancer Res Treat; 2020; 19():1533033820945817. PubMed ID: 32812493
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
9. Clinical Value of lncRNA LUCAT1 Expression in Liver Cancer and its Potential Pathways.
Jiao Y; Li Y; Ji B; Cai H; Liu Y
J Gastrointestin Liver Dis; 2019 Dec; 28(4):439-447. PubMed ID: 31826070
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
11. Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver Cancer and Their Clinical and Prognostic Significance.
Li Y; Jiao Y; Li Y; Liu Y
Dis Markers; 2019; 2019():1569049. PubMed ID: 31772683
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
Yu B; Ding Y; Liao X; Wang C; Wang B; Chen X
Dig Dis Sci; 2019 Oct; 64(10):2878-2892. PubMed ID: 30949905
[TBL] [Abstract][Full Text] [Related]
13. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans.
Männistö VT; Simonen M; Hyysalo J; Soininen P; Kangas AJ; Kaminska D; Matte AK; Venesmaa S; Käkelä P; Kärjä V; Arola J; Gylling H; Cederberg H; Kuusisto J; Laakso M; Yki-Järvinen H; Ala-Korpela M; Pihlajamäki J
Liver Int; 2015 Jul; 35(7):1853-61. PubMed ID: 25533197
[TBL] [Abstract][Full Text] [Related]
14.
Jiao Y; Li Y; Fu Z; Hou L; Chen Q; Cai Y; Jiang P; He M; Yang Z
Dis Markers; 2019; 2019():9037131. PubMed ID: 31781311
[TBL] [Abstract][Full Text] [Related]
15. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
16. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer.
Zhu HZ; Zhou WJ; Wan YF; Ge K; Lu J; Jia CK
World J Gastroenterol; 2020 Feb; 26(8):804-817. PubMed ID: 32148378
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of 3-hydroxybutyrate dehydrogenase 1 is a prognostic marker and promotes tumor progression in hepatocellular carcinoma.
Luo W; Wu S; Zhang F; Chen X; Ma Y; Mo Y
Pathol Res Pract; 2022 Oct; 238():154111. PubMed ID: 36115334
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.
Tang H; You T; Sun Z; Bai C
BMC Cancer; 2022 Feb; 22(1):197. PubMed ID: 35189839
[TBL] [Abstract][Full Text] [Related]
20. DEP domain containing 1 is a novel diagnostic marker and prognostic predictor for hepatocellular carcinoma.
Yuan SG; Liao WJ; Yang JJ; Huang GJ; Huang ZQ
Asian Pac J Cancer Prev; 2014; 15(24):10917-22. PubMed ID: 25605201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
